News
06-05-2023, 07:00 PM
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.
More... (https://www.news-medical.net/news/20230605/HER2-targeted-antibody-drug-conjugate-shows-encouraging-responses-long-lasting-clinical-benefit-in-several-tumor-types.aspx)
More... (https://www.news-medical.net/news/20230605/HER2-targeted-antibody-drug-conjugate-shows-encouraging-responses-long-lasting-clinical-benefit-in-several-tumor-types.aspx)